Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1033 of 6351
-
DNA vaccines aim to supercharge immune therapy against skin cancer
Disease control OngoingThe purpose of this study is to find out if two new treatment cancer vaccines called SCIB1 and iSCIB1+ can be used safely when added to nivolumab (Opdivo) with ipilimumab (Yervoy), or SCIB1 with pembrolizumab (Keytruda). Pembrolizumab or nivolumab with ipilimumab are standard tre…
Phase 2 • Sponsor: Scancell Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug combo shows promise for rare uterine cancer
Disease control OngoingThis phase II trial studies olaparib and temozolomide in treating patients with uterine leiomyosarcoma (LMS) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), that has spread from where it first started to oth…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New combo therapy aims to supercharge immune attack on tough cancers
Disease control CompletedThis phase I/II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and nivolumab with or without stereotactic body radiation th…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Can video games rebuild arm strength in cerebral palsy?
Symptom relief PausedVirtual reality (VR) has shown to be effective to improve arm function in children with cerebral palsy (CP). Recently, functional strength training (FST) starts to show to improve arm function in patients with stroke but has not been extensively explored in children with CP. This…
Sponsor: Georgia State University • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC
-
New drug M281 aims to tame rare blood disorder
Disease control OngoingThe main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).
Phase 2/3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
A gentle brain zap might boost medication adherence in schizophrenia
Disease control OngoingThis study seeks to explore the effects of transcranial direct current stimulation (tDCS), a non-invasive method of brain stimulation, as an adjunctive treatment to improve antipsychotic medication adherence in patients with schizophrenia (SCZ). The investigators hypothesize that…
Sponsor: Centre for Addiction and Mental Health • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Brain metastases trial: can adding radiation boost immunotherapy?
Disease control Recruiting nowThis is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.
Phase 2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis phase II trial studies how well venetoclax and acalabrutinib work in treating patients with mantle cell lymphoma that did not respond to previous treatment or has come back. Venetoclax may cause cancer cell death by blocking the mechanism that cancer cells use to stay alive.…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Genetically modified t cells take on rare sarcomas
Disease control OngoingThis is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A\*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .
Phase 2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could a 7-Week lifestyle combo reshape blood sugar control?
Disease control CompletedThis project will determine the independent and combined effects of high intensity interval training and time-restricted eating on blood sugar regulation among women in reproductive-age who have overweight or obesity. The intervention period will be seven weeks. Before and after …
Sponsor: Norwegian University of Science and Technology • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug duo aims to shrink Hard-to-Treat prostate tumors
Disease control Recruiting nowThe main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escal…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Fetal stem cells aim to mend broken bones in infants
Disease control OngoingAn exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a com…
Phase 1/2 • Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC
-
New hope for blood cancer patients: experimental drug CCS1477 enters human trials
Disease control Recruiting nowA Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Phase 1/2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Steering brain signals: new electrodes aim to ease Parkinson's symptoms
Disease control CompletedThe primary objective of the study is to determine if subthalamic nucleus (STN) deep brain stimulation (DBS) using the Vercise directional leads improves neuropsychiatric state and neuropsychiatric fluctuations 12 months after surgery in a large consecutive series of STN-DBS Park…
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo therapy shows promise for slowing spread of prostate cancer
Disease control CompletedThis is a Phase II non-blinded randomized study evaluating men with oligometastatic prostate cancer lesions randomized (1:1) to stereotactic ablative radiation therapy (SABR) versus SBAR + Radium-223. We are looking to determine the progression-free survival of men who have oligo…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Can a common diabetes pill make insulin therapy safer and more effective for type 1 diabetes?
Disease control OngoingPurpose: To examine the effect of addition of combination therapy with dapagliflozin plus pioglitazone to insulin on glucose control and plasma ketone concentration in patients with type 1 diabetes (T1DM) Research Design: 120 patients with type 1 diabetes who otherwise are health…
Phase 4 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a new drug match a standard anemia treatment for dialysis patients?
Disease control CompletedThis is a double-blind, two-arm, randomized, multicenter to compare the efficacy and safety of NNG-DEPO and Aranesp in CKD on dialysis patients. Patients aged 18 to 65 years (inclusive), diagnosed with anemia due to CKD in dialysis, who meet all inclusion criteria, requiring tre…
Phase 3 • Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Immunotherapy combo shows promise for early lung cancer
Disease control OngoingNivolumab (BMS-936558) is a fully human, IgG4 (kappa) isotype mAb that binds PD-1 on activated immune cells and disrupts engagement of the receptor with its ligands PD-L1 (B7 H1/CD274) and PD-L2 (B7-DC/CD273), thereby abrogating inhibitory signals and augmenting the host antitumo…
Phase 2 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New shot aims to stop liver damage in rare genetic disease
Disease control CompletedThe purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).
Phase 2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy for Hard-to-Treat gut tumors enters final testing phase
Disease control Recruiting nowNeuroendocrine tumours (NETs), better defined as neoplasms (NENs), are a heterogeneous group of neoplasms that range from well-differentiated tumours to more aggressive carcinomas. Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the established standard…
Phase 3 • Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC